Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
0.9791
+0.0191 (1.99%)
At close: Apr 22, 2026, 4:00 PM EDT
0.9893
+0.0102 (1.04%)
After-hours: Apr 22, 2026, 6:29 PM EDT
Jasper Therapeutics Employees
Jasper Therapeutics had 22 employees as of December 31, 2025. The number of employees decreased by 42 or -65.63% compared to the previous year.
Employees
22
Change
-42
Growth
-65.63%
Revenue / Employee
n/a
Profits / Employee
-$3,445,500
Market Cap
27.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 22 | -42 | -65.63% |
| Sep 30, 2025 | 27 | -37 | -57.81% |
| Dec 31, 2024 | 64 | 19 | 42.22% |
| Dec 31, 2023 | 45 | 10 | 28.57% |
| Dec 31, 2022 | 35 | 10 | 40.00% |
| Sep 30, 2022 | 36 | 14 | 63.64% |
| Jun 30, 2022 | 35 | 11 | 45.83% |
| Mar 31, 2022 | 34 | 12 | 54.55% |
| Dec 31, 2021 | 25 | 3 | 13.64% |
| Sep 30, 2021 | 22 | - | - |
| Jun 30, 2021 | 24 | - | - |
| Mar 31, 2021 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Longeveron | 38 |
| Kyntra Bio | 34 |
| Lantern Pharma | 16 |
| Apollomics | 13 |
| Tvardi Therapeutics | 12 |
| NanoViricides | 7 |
| Dyadic International | 6 |
JSPR News
- 23 days ago - Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference - GlobeNewsWire
- 3 months ago - Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria - GlobeNewsWire
- 3 months ago - Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth - GlobeNewsWire
- 5 months ago - Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation - GlobeNewsWire
- 5 months ago - Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation - GlobeNewsWire
- 5 months ago - Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 5 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - Newsfile Corp